Sarunyou Chusri

Prof. Dr. Sarunyou Chusri

Prince of Songkla University, Hat Yai Campus
orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2022 in Emerging Infectious Diseases
Verified
Journal Article
Open access
PDF file
TSThanit Sila
Thanit Sila
JSJutapoln Sunghan
Jutapoln Sunghan
WLWison Laochareonsuk
Wison Laochareonsuk
SSSmonrapat Surasombatpattana
Smonrapat Surasombatpattana
CKChanon Kongkamol
Chanon Kongkamol
SCSarunyou Chusri
Sarunyou Chusri
Suspected Cat-to-Human Transmission of SARS-CoV-2

1 August 2011 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Closed access
SCSarunyou Chusri
Sarunyou Chusri
PSPisud Siripaitoon
Pisud Siripaitoon
SHSiriporn Hirunpat
Siriporn Hirunpat
KSKhachornsakdi Silpapojakul
Khachornsakdi Silpapojakul
There has been a recent increase in reports of neurologic complications as major causes of morbidity and mortality in chikungunya virus infection. As a part of 2004–2009 global outbreaks, an unprecedented large chikungunya epidemic occurred in Southern Thailand during 2008–2009 in which 49,069 cases were reported. During this period, we encountered two patients with meningoencephalitis and another patient with myeloneuropathy among 1,018 cases diagnosed as chikungunya in our hospital. The clinical pictures are presented and the key points are used to recognize and differentiate chikungunya from Japanese encephalitis virus, dengue virus, and herpesvirus infections, which are more common causes of meningoencephalitis and myelitis in this region.

6 January 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JOJulalak C. Ontong
Julalak C. Ontong
NONwabor F. Ozioma
Nwabor F. Ozioma
SVSupayang P. Voravuthikunchai
Supayang P. Voravuthikunchai
SCSarunyou Chusri
Sarunyou Chusri
Multidrug resistant Enterobacterales have become a serious global health problem, with extended hospital stay and increased mortality. Antibiotic monotherapy has been reported ineffective against most drug resistant bacteria including Klebsiella pneumoniae, thus encouraging the use of multidrug therapies as an alternative antibacterial strategy. The present works assessed the antibacterial activity of colistin against K. pneumoniae isolates. Resistant isolates were tested against 16 conventional antibiotics alone and in combination with colistin. The results revealed that all colistin resistant isolates demonstrated multidrug resistance against the tested antibiotics except amikacin. At sub-inhibitory concentrations, combinations of colistin with amikacin, or fosfomycin showed synergism against 72.72% (8 of 11 isolates). Colistin with either of gentamicin, meropenem, cefoperazone, cefotaxime, ceftazidime, moxifloxacin, minocycline, or piperacillin exhibited synergism against 81.82% (9 of 11 isolates). Combinations of colistin with either of tobramycin or ciprofloxacin showed synergism against 45.45% (5 in 11 isolates), while combinations of colistin with imipenem or ceftolozane and tazobactam displayed 36.36% (4 of 11 isolates) and 63.64% (7 of 11 isolates) synergism. In addition, combinations of colistin with levofloxacin was synergistic against 90.91% (10 of 11 isolates). The results revealed that combinations of colistin with other antibiotics could effectively inhibit colistin resistant isolates of K. pneumoniae, and thus could be further explore for the treatment of multidrug resistant pathogens.

6 January 2022 in Computational and Structural Biotechnology Journal
Verified
Journal Article
Open access
ACArnon Chukamnerd
Arnon Chukamnerd
KSKamonnut Singkhamanan
Kamonnut Singkhamanan
VCVirasakdi Chongsuvivatwong
Virasakdi Chongsuvivatwong
PPPrasit Palittapongarnpim
Prasit Palittapongarnpim
YDYohei Doi
Yohei Doi
Komwit SurachatKomwit Surachat
Komwit Surachat
The worldwide spread of carbapenem-resistant Acinetobacter baumannii (CRAB) has become a healthcare challenge for some decades. To understand its molecular epidemiology in Southern Thailand, we conducted whole-genome sequencing (WGS) of 221 CRAB clinical isolates. A comprehensive bioinformatics analysis was performed using several tools to assemble, annotate, and identify sequence types (STs), antimicrobial resistance (AMR) genes, mobile genetic elements (MGEs), and virulence genes. ST2 was the most prevalent ST in the CRAB isolates. For the detection of AMR genes, almost all CRAB isolates carried the blaOXA-23 gene, while certain isolates harbored the blaNDM-1 or blaIMP-14 genes. Also, various AMR genes were observed in these CRAB isolates, particularly aminoglycoside resistance genes (e.g., armA, aph(6)-Id, and aph(3″)-Ib), fosfomycin resistance gene (abaF), and tetracycline resistance genes (tet(B) and tet(39)). For plasmid replicon typing, RepAci1 and RepAci7 were the predominant replicons found in the CRAB isolates. Many genes encoding for virulence factors such as the ompA, adeF, pgaA, lpxA, and bfmR genes were also identified in all CRAB isolates. In conclusion, most CRAB isolates contained a mixture of AMR genes, MGEs, and virulence genes. This study provides significant information about the genetic determinants of CRAB clinical isolates that could assist the development of strategies for improved control and treatment of these infections.

23 November 2021 in Vaccines
Verified
Journal Article
Open access
PDF file
PIPORNTIP INTAPIBOON
PORNTIP INTAPIBOON
PSPurilap Seepathomnarong
Purilap Seepathomnarong
JOJomkwan Ongarj
Jomkwan Ongarj
SSSmonrapat Surasombatpattana
Smonrapat Surasombatpattana
SUSupattra Uppanisakorn
Supattra Uppanisakorn
Nawamin PinpathomratNawamin Pinpathomrat
Nawamin Pinpathomrat
Effective vaccine coverage is urgently needed to tackle the COVID-19 pandemic. Inactivated vaccines have been introduced in many countries for emergency usage, but have only provided limited protection. Heterologous vaccination is a promising strategy to maximise vaccine immunogenicity. Here, we conducted a phase I, randomised control trial to observe the safety and immunogenicity after an intradermal boost, using a fractional dosage (1:5) of BNT162b2 mRNA vaccine in healthy participants in Songkhla, Thailand. In total, 91 volunteers who had been administered with two doses of inactivated SARS-CoV-2 (CoronaVac) were recruited into the study, and then randomised (1:1:1) to received different regimens of the third dose. An intramuscular booster with a full dose of BNT162b2 was included as a conventional control, and a half dose group was included as reciprocal comparator. Both, immediate and delayed adverse events following immunisation (AEFI) were monitored. Humoral and cellular immune responses were examined to observe the booster effects. The intradermal booster provided significantly fewer systemic side effects, from 70% down to 19.4% (p < 0.001); however, they were comparable to local reactions with the conventional intramuscular booster. In the intradermal group after receiving only one fifth of the conventional dosage, serum Anti-RBD IgG was halved compared to the full dose of an intramuscular injection. However, the neutralising function against the Delta strain remained intact. T cell responses were also less effective in the intradermal group compared to the intramuscular booster. Together, the intradermal booster, using a fractional dose of BNT162b2, can reduce systemic reactions and provides a good level and function of antibody responses compared to the conventional booster. This favourable intradermal boosting strategy provides a suitable alternative for vaccines and effective vaccine management to increase the coverage during the vaccine shortage.

1 October 2019 in Journal of Microbiology, Immunology and Infection
Verified
Journal Article
Open access
SCSarunyou Chusri
Sarunyou Chusri
VCVirasakdi Chongsuvivatwong
Virasakdi Chongsuvivatwong
KSKachornsakdi Silpapojakul
Kachornsakdi Silpapojakul
KSKamonnut Singkhamanan
Kamonnut Singkhamanan
THThanaporn Hortiwakul
Thanaporn Hortiwakul
YDYohei Doi
Yohei Doi
We aimed to characterize clinical manifestations of the patients with bacteremia due to community-acquired Acinetobacter baumannii and evaluate the outcomes of these patients. We conducted a retrospective study to include adult patients with A. baumannii bacteremia and then classified them into two groups: community-acquired A. baumannii bacteremia and hospital-acquired A. baumannii bacteremia. Characteristics and outcomes between 2 groups were compared. The Galleria mellonella infection survival model was used to determine the virulence of A. baumannii in these 2 groups. There were 63 patients with A. baumannii bacteremia: 21 patients with community-acquired (CA) bacteremia and 42 patients with hospital-acquired (HA) bacteremia. Three patients with CA bacteremia were excluded due to healthcare-associated risks of infection. The remaining 18 patients with CA bacteremia had carbapenem-susceptible A. baumannii (CA-CSAB). Among the 42 patients with HA bacteremia, 11 patients had carbapenem-susceptible A. baumannii (HA-CSAB) and 31 patients had carbapenem-resistant A. baumannii (HA-CRAB). The 30-day mortality rates of those with CA-CSAB did not differ from those with HA-CSAB bacteremia but were significantly lower than those with HA-CRAB (p = 0.003). The factors influencing 30-day mortality were infection with CRAB (p = 0.004), appropriate empirical antimicrobial therapy (p = 0.002), and higher Acute Physiology and Chronic Health Evaluation II score (p < 0.001). The G. mellonella assay showed no differences in survival rates among CA-CSAB, HA-CSAB, and HA-CRAB. Patients with bacteremia due to CA-CSAB and HA-CSAB had similar outcomes. Similar virulences of CA-CSAB and HA-CSAB were confirmed with the G. mellonella infection model.